Gilead CEO Daniel O'Day (Photo by Paras Griffin/Getty Images for ESSENCE)
Gilead's M&A appetite is for deals in the 'mid-single-digit billions,' CEO says
Gilead CEO Daniel O’Day says the company will likely look for more deals like its $4.3 billion purchase of CymaBay Therapeutics …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
